Telos Partners, LLC, a firm providing scientific, regulatory and publication services to the life sciences industry, has been selected by Acera Surgical to lead its Restrata™ wound matrix study titled: “Clinical Outcomes after Treatment with Restrata™ in Diabetic Foot Ulcers (DFU): A Case Series of Initial Effectiveness and Safety Measures.”
The clinical trial is a multi-center, single-arm study designed to evaluate 12-week outcomes after applying Acera’s Restrata™ Wound Matrix to patients with diabetic foot ulcers (DFU). Restrata™ is a next-generation, fully synthetic wound matrix which was FDA cleared for wound indications in April 2017.
Read next article: Telos Partners Moderates Panel Discussion at JLABS in Toronto